Phase II study evaluating the efficacy of Lenalidomide in association with Rituximab in refractory or relapse of primary central nervous system lymphoma (PCNSL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Lymphoma
- Focus Therapeutic Use
- Acronyms REVRI
- 23 Aug 2017 Planned End Date changed from 1 May 2021 to 1 Jan 2019.
- 23 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.